CANF Bought shares of canfite today at $2.85. This is a low float bio with phase 2/3 topline psoriasis results expected in Q1 2015. Company has orphan designation for cf102 liver drug, which has been approved for compassionate use in Israel. March 2014 $5 million raise was done at $5.15 a share. With the IBB setting new highs, CANF has been making new lows.